Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CARA Stock Forecast 2026-2027
$15.96
Current Price
$8.11M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CARA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CARA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+19.3%
1 Year Change
0.0%
Year-to-Date Change
-49.0%
From 52W High of $31.32
+96.4%
From 52W Low of $8.13
📊 TOP ANALYST CALLS
Did CARA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cara Therapeutics is one of their latest high-conviction picks.
Latest CARA Stock Price Targets & Analyst Predictions
CARA has shown a year-to-date change of 0.0% and a 1-year change of 19.3%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CARA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CARA Analyst Ratings
0
Buy
1
Hold
0
Sell
CARA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $15.96
Latest CARA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CARA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 13, 2024 | Needham | Joseph Stringer | Hold | Downgrade | $N/A |
| Jun 13, 2024 | HC Wainwright & Co. | Oren Livnat | Neutral | Downgrade | $N/A |
| Jun 13, 2024 | Canaccord Genuity | Sumant Kulkarni | Hold | Downgrade | $1.00 |
| May 23, 2024 | Needham | Buy | Reiterates | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 14, 2024 | Needham | Buy | Reiterates | $N/A | |
| Apr 10, 2024 | Needham | Buy | Reiterates | $N/A | |
| Mar 6, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 5, 2024 | Needham | Buy | Reiterates | $N/A | |
| Jan 22, 2024 | Needham | Buy | Maintains | $N/A | |
| Dec 19, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 18, 2023 | Needham | Buy | Maintains | $N/A | |
| Nov 14, 2023 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Oct 19, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 8, 2023 | Needham | Buy | Reiterates | $N/A | |
| Aug 8, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jun 27, 2023 | Jefferies | Buy | Reiterates | $N/A | |
| Jun 27, 2023 | Stifel | Buy | Reiterates | $N/A | |
| May 16, 2023 | B of A Securities | Underperform | Maintains | $N/A | |
| May 16, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Cara Therapeutics, Inc. (CARA) Competitors
The following stocks are similar to Cara Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cara Therapeutics, Inc. (CARA) Financial Data
Cara Therapeutics, Inc. has a market capitalization of $8.11M with a P/E ratio of -1.0x. The company generates $7.14M in trailing twelve-month revenue with a 91.3% profit margin.
Revenue growth is -51.6% quarter-over-quarter, while maintaining an operating margin of -412.4% and return on equity of -270.0%.
Valuation Metrics
Market Cap
$8.11M
Enterprise Value
$30.88M
P/E Ratio
-1.0x
PEG Ratio
-6.9x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
-51.6%
Gross Margin
+100.0%
Operating Margin
-412.4%
Net Margin
+91.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+155.8%
Current Ratio
11.0x
Debt/Equity
-9.7x
ROE
-270.0%
ROA
-41.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cara Therapeutics, Inc. (CARA) Business Model
About Cara Therapeutics, Inc.
What They Do
Develops therapeutics for chronic pruritus.
Business Model
Cara Therapeutics focuses on developing and commercializing treatments for chronic pruritus, primarily through its lead product, KORSUVA, designed for patients with chronic kidney disease undergoing hemodialysis. The company generates revenue through product sales and strategic licensing agreements with pharmaceutical partners in Japan and South Korea, enabling wider distribution and development of its drugs.
Additional Information
Incorporated in 2004 and headquartered in Stamford, Connecticut, Cara Therapeutics is advancing its pipeline with additional formulations of difelikefalin, currently in clinical trials, to address various forms of chronic pruritus, indicating a robust potential for growth in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
10
CEO
Mr. Christopher A. Posner
Country
United States
IPO Year
2014
Website
www.caratherapeutics.comCara Therapeutics, Inc. (CARA) Latest News & Analysis
Latest News
Quick Summary
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has been formed through a merger and is focused on developing treatments targeting STAT3 for fibrosis-driven diseases.
Why It Matters
The merger forms a Nasdaq-listed entity focused on innovative STAT3 treatments, potentially attracting investor interest due to growth prospects in a high-demand healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cara Therapeutics, Inc. announced a 1-for-3 reverse stock split of its outstanding shares, approved by its Board of Directors, effective April 14, 2025.
Why It Matters
A 1-for-3 reverse stock split may indicate efforts to boost the stock price and meet listing requirements, impacting liquidity, investor perception, and overall market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti, LLC is investigating the proposed merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc., which would result in Cara shareholders owning about 17% of the new entity.
Why It Matters
The investigation into Cara Therapeutics' merger may signal potential legal or regulatory issues, impacting shareholder confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cara Therapeutics will execute a 1-for-12 reverse stock split and reduce its authorized shares from 200 million to 16.67 million, effective December 30, 2024, at 5:00 p.m. ET.
Why It Matters
Cara Therapeutics' reverse stock split may enhance share price but indicates potential financial distress, impacting investor perception and future capital raising efforts.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A proposed merger aims to establish a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing treatments targeting STAT3 for fibrosis-driven diseases.
Why It Matters
The merger could enhance market value and attract investment by combining resources for innovative treatments, potentially leading to significant breakthroughs in fibrosis-driven disease therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monteverde & Associates is investigating Cara Therapeutics (NASDAQ: CARA) regarding its merger with Tvardi Therapeutics, where CARA shareholders will own about 17% of the new entity.
Why It Matters
The investigation into Cara Therapeutics' merger with Tvardi could impact shareholder value and market perception, affecting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CARA Stock
What is Cara Therapeutics, Inc.'s (CARA) stock forecast for 2026?
Analyst forecasts for Cara Therapeutics, Inc. (CARA) are not currently available. The stock is trading at $15.96.
Is CARA stock a good investment in 2026?
According to current analyst ratings, CARA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CARA stock?
Price predictions from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is Cara Therapeutics, Inc.'s business model?
Cara Therapeutics focuses on developing and commercializing treatments for chronic pruritus, primarily through its lead product, KORSUVA, designed for patients with chronic kidney disease undergoing hemodialysis. The company generates revenue through product sales and strategic licensing agreements with pharmaceutical partners in Japan and South Korea, enabling wider distribution and development of its drugs.
What is the highest forecasted price for CARA Cara Therapeutics, Inc.?
Price targets from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is the lowest forecasted price for CARA Cara Therapeutics, Inc.?
Price targets from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is the overall CARA consensus from analysts for Cara Therapeutics, Inc.?
The overall analyst consensus for CARA is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CARA stock price projections?
Stock price projections, including those for Cara Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 2:58 AM UTC